New Zealand firm Rua Bioscience has achieved unaudited revenue of NZ$694k for the six months ending December 31, 2024, up 16% on its previous forecast.

During a capital raise in late last year, Rua had forecast sales of $600,000 for the period.
It attributed the increase to “robust growth” in its key markets – Germany, Australia, and New Zealand – and strong sales of its new dried flower products.
It said Germany continues to see rising demand on the back of regulatory changes introduced in April last year.
CEO Paul Naske said the results proved the effectiveness of the firm’s export-led strategy and “provides evidence that we are delivering on our plans”.
The company’s priorities for the rest of FY25 include working with suppliers to increase volumes to meet demand in key markets and expanding its product portfolio.